Gilead late yesterday imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies. It is the 15th manufacturer to place restrictions on its 340B contract pharmacy program.
The policy, which applies to hospital and grantee entities, comes in the same week that entities became aware of an apparent change in Gilead’s HIV drug reimbursement practices that is giving contract pharmacies second thoughts on whether they want to continue to partner with 340B providers.
Gilead late yesterday imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
